loading page

A review SARS-CoV-2 the other face to SARS-CoV and MERS-CoV: About future predictions
  • +1
  • Tarek Abdelghany,
  • Magdah Ganash,
  • Marwah Bakri,
  • Nadeem El-Hussieny
Tarek Abdelghany
Al-Azhar University Faculty of Science
Author Profile
Magdah Ganash
King Abdulaziz University Faculty of Sciences
Author Profile
Marwah Bakri
Jazan University
Author Profile
Nadeem El-Hussieny
National Research Centre
Author Profile


The COVID-19 outbreak is proving to be an unprecedented disaster in all world on health, social and economic cases. Understanding of COVID-19 diagnosis and its epidemic is on-going until now, but from the events of SARS-CoV and MERS-CoV in the last 18 years, besides genomic similarity where SARS-CoV, MERS-CoV and SARS-CoV-2 have positive-sense RNA genomes of 27.9kb, 30.1kb and 29.9kb, respectively. All precautions that done during SARS-CoV and MERS-CoV infections may contribute in the current days for avoid infection by SARS-CoV-2. All trials failed to produce vaccines for SARS-CoV and MERS-CoV, therefore the current review predict that also all trials for SARS-CoV-2 will not succeed, the sole solution for treatment of this infection, research for antiviral drugs or drugs that enhance the immune system. The mortality rate caused by the SARS-CoV and MERS-CoV was reached 15% and 37%, respectively. The first declarations about mortality rate of SARS-CoV-2 was around 2%-5% but now differed around the world and reached more than 13% in some countries. We expected that the realistic scenario of COVID-19 outbreaks or incidence would continue for at minimum three years with decreasing the number of infected cases, unless the world discover vaccines or drug that inhibit the replication of virus.